Taken together, our results suggest that deficient expression of pAMPK in Parkin or PINK1 mutant midbrains may contribute to bioenergetics impairments in DA neurons and precipitate PD, and that pharmacological AMPK activation may represent a neuroprotective strategy for the disease. Here, PRKN is linked to Parkinson disease.